Swedish Orphan Biovitrum AB

SOBI NPV
Create an alert
Sell441.20 SEK
Buy443.00 SEK
3.80 SEK (0.87%)
Last updated today at
Trade
Back to dashboard

Company Information

About this company

Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.

Key people

David Meek
Independent Chairman of the Board
Mahmood Ladha
Head - Strategic Transformation Operations
Norbert Oppitz
Head - International
Mats Lek
Director, Employee Representative
Katy Mazibuko
Director, Employee Representative
Asa Christina Riisberg
Director
Sven Anders Ullman
Senior Vice President of Research and Development, Chief Scientific Officer
Guido Oelkers
Chief Executive Officer
Henrik Stenqvist
Chief Financial Officer
Christine Wesstroem
Head - Technical Operations
Torbjoern Hallberg
General Counsel and Head - Legal Affairs
Lydia Abad-Franch
Chief Medical Officer, Head - Research and Development and Medical Affairs
Duane H. Barnes
Head - North America
Lena Bjurner
Head - People and Communication
Sofiane Fahmy
Head - Europe
Click to see more

Key facts

  • Shares in issue
    357.41m
  • EPIC
    SOBI
  • ISIN
    SE0000872095
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    SEK 156.43bn
  • Employees
    2,119
  • Exchange
    Stockholm Stock Exchange
  • Index
    SX All Share PI Market Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.